How mitochondria drives senescence, affecting healthy ageing
EurekAlert! - 20-Feb-2020Potential target for drug-based interventions to delay cellular ageing identified
Join the club for FREE to access the whole archive and other member benefits.
President of Glenn Foundation for Medical Research
Mark R. Collins is an Executive In Residence with Cycad Group, and together with Paul and Leonard was one of the co-founders of Cycad Group. Mark currently serves as the President of the Glenn Foundation for Medical Research. Prior to joining Cycad Group Mark has had a career in consulting and in marketing management in the medical device anddiagnostic industry. He has held managerial positions in several private life science companies that were acquired by public companies, and has served as a member of the board of directors of a some of Cycad Group’s portfolio companies. Mark also serves as a member of the Board of Directors of the American Federation For Aging Research.
Visit website: https://glennfoundation.org/about/
See also: Glenn Foundation For Medical Research - The mission of the Glenn Foundation For Medical Research is to extend the healthy years of life
Details last updated 22-Feb-2020
Potential target for drug-based interventions to delay cellular ageing identified
HDAC inhibitor shows beneficial effects in mice but too toxic for healthy humans